Colorectal Cancer Clinical Trial
Official title:
Phase I/II Study of the Tumor-targeting Human L19TNFα Monoclonal Antibody-cytokine Fusion Protein in Patients With Advanced Solid Tumors
The recombinant human fusion protein L19TNFα was created with the intention to overcome the systemic toxicity of TNFα by directly targeting it to tumor tissues. Tumor-targeted L19TNFα would result in high and sustained intralesional bioactive TNFα concentrations.
Status | Completed |
Enrollment | 34 |
Est. completion date | September 2011 |
Est. primary completion date | May 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Phase I: histologically or cytologically confirmed relapsed or refractory locally advanced or metastatic solid tumor of any origin, not amenable to standard therapy. - Phase II: histologically or cytologically confirmed relapsed or refractory locally advanced or metastatic colorectal cancer not amenable to standard therapy. - For both phase I and II: - Subjects aged = 18 years. - ECOG performance status = 2. - Subjects must have at least one unidimensionally measurable lesion by computed tomography as defined by RECIST criteria (see Section 8) or tumour markers parameters of disease such as PSA and CA125 for Prostate cancer and Ovarian cancer, respectively. This lesion must not have been irradiated during previous treatments. - Absolute neutrophil count (ANC) = 1.5 x 10^9/L, platelets = 100 x 10^9/L, and haemoglobin (Hb) = 9.5 g/dl. - All acute adverse effects (excluding alopecia) of any prior therapy (including surgery, radiation therapy, chemotherapy) must have resolved to = Grade 1, except elevated liver transaminases judged to be associated with tumor infiltration (see below) (graded according to National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events, version 3.0 [CTCAE, v.3.0]). - Alkaline phosphatase (ALP), alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) = 2.5 x upper limit of normal (ULN), and total bilirubin = 2.0 mg/gL unless liver involvement by the tumor, in which case the transaminase levels up to 5 x ULN are allowed. - Creatinine = 1.5 ULN or 24 h creatinine clearance = 60 mL/min. - Testing negative for acute or chronic infection with hepatitis B or C virus, or human immunodeficiency virus 1 or 2. - Negative pregnancy test for females of childbearing potential at the screening visit. - Commitment from subject to practice medically appropriate/acceptable method of birth control (e.g., hormonal, condoms or other adequate barrier controls, intrauterine contraceptive device, or sterilization) beginning at the screening visit and continuing until 3 months following the last treatment with study drug. - Able to provide written Informed Consent. Exclusion Criteria: - Breastfeeding women. - Presence of active infections (e.g. requiring antimicrobial therapy) or other severe concurrent disease, which, in the opinion of the Investigator, would place the subject at undue risk or interfere with the study. - Known brain metastases or signs and/or symptoms suggestive of brain metastases. - Known cancer of other primary origin (excluding Stage I non-melanoma skin cancer) within the prior 5 years. - Active autoimmune disease. - Cardiac disease as manifested by any of the following: - > Grade II heart failure, graded per New York Heart Association (NYHA) criteria. - Unstable angina pectoris. - Acute or subacute coronary syndromes, including myocardial infarction, occurring with 1 year prior to study treatment. - Arrhythmia needing continuous treatment. - Ejection fraction less than the institutional lower limit of normal as assessed by multigated radionuclide angiography (MUGA) scan or echocardiogram. - Uncontrolled hypertension. - Ischemic peripheral vascular disease (Grade IIb-IV). - Severe diabetic retinopathy. - Major surgery or trauma within 4 weeks prior to start of study treatment. - Known history of allergy to TNFa or other intravenously administered human proteins/peptides/antibodies. - Chemotherapy, radiation therapy or therapy with an investigational agent within 4 weeks prior start of study treatment. - Previous in vivo exposure to monoclonal antibodies for biological therapy in the 6 weeks before administration of study treatment. - Growth factors or immunomodulatory agents within 7 days prior to the administration of the study treatment. - Subject requires or is taking corticosteroids or other immunosuppressant drugs on a long-term basis. Limited use of corticosteroids to treat or prevent acute hypersensitivity reactions is not considered an exclusion criterion. - Concurrent therapy with warfarin at doses greater than 1 mg/day or equivalent doses of other coumarin derivatives. - Participation in another interventional clinical trial during participation in this trial. - Expectation that the subject will not be able to complete at least 6 weeks of therapy. - Any conditions that in the opinion of the Investigator could hamper compliance with the study protocol. |
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Italy | A.O. UNIVERSITARIA OSPEDALI RIUNITI - OSPEDALE UMBERTO I DI ANCONA - ANCONA (Italy) | Ancona | |
Italy | European Istitue of Oncology Milan (Italy) | Milan |
Lead Sponsor | Collaborator |
---|---|
Philogen S.p.A. | Eudax S.r.l., InnoPharma Inc. |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Phase I: Determination of the Maximum Tolerated Dose (MTD) and Recommended Dose (RD) | Determination of the Maximum Tolerated Dose (MTD) and Recommended Dose (RD) of L19TNFa. | day 1-29 | Yes |
Primary | Phase II: Investigation of the anti-cancer activity of L19TNFa as measured by Objective Response Rate (ORR) | Investigation of the anti-cancer activity of L19TNFa as monotherapy as measured by the Objective Response Rate (ORR) at the end of cycle 2 in subjects with relapsed or refractory locally advanced or metastatic colorectal cancer not amenable to standard systemic therapy. | within day 42 | No |
Secondary | Investigation of serum concentrations of L19TNFa (pharmacokinetic properties) | day 1-5 | No | |
Secondary | Investigation of the induction of human anti-fusion protein antibody (HAFA) | 1-16 months | Yes | |
Secondary | Investigation of early signs of anti-tumor activity of L19TNFa | Investigation of early signs of anti-tumor activity of L19TNFa as measured by Objective Response Rate (ORR) at the end of cycle 2, median Progression-Free Survival (PFS) and median Overall Survival (OS). | 14 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |